Free Trial
ETR:BAYN

Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis

€28.09
-0.30 (-1.06%)
(As of 06/7/2024 ET)
Today's Range
€27.75
€28.38
50-Day Range
€26.08
€29.38
52-Week Range
€24.96
€54.95
Volume
2.67 million shs
Average Volume
N/A
Market Capitalization
$27.60 billion
P/E Ratio
N/A
Dividend Yield
0.39%
Price Target
N/A
BAYN stock logo

About Bayer Aktiengesellschaft Stock (ETR:BAYN)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

BAYN Stock Price History

BAYN Stock News Headlines

Feier ohne Bayer - Aktie taucht (mal wieder) ab
BASF und Bayer: Bald wieder aufwärts?
Bayer: Jetzt gut aufpassen!
Bayer AG Cedear BAYN
What Wall Street expects from Bayer's earnings
Bayer nach den Zahlen: Kurs steigt auf 30 Euro
Bayer Q1 Profit Down; Confirms FY Currency-adj. Forecast
See More Headlines
Receive BAYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
96,931
Year Founded
N/A

Profitability

Net Income
$-3,120,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$47.01 billion
Cash Flow
€4.91 per share
Book Value
€36.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$27.60 billion
Optionable
Not Optionable
Beta
0.97
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. William N. Anderson (Age 58)
    Chairman of the Management Board & CEO
    Comp: $8.43M
  • Mr. Wolfgang U. Nickl (Age 55)
    CFO & Member of Management Board
    Comp: $1.98M
  • Mr. Heiko W. J. Schipper (Age 55)
    Member of Management Board & President of the Consumer Health Division
    Comp: $1.95M
  • Mr. Stefan Oelrich (Age 56)
    Head of the Pharmaceuticals Division & Member of the Board of Management
    Comp: $1.95M
  • Mr. Rodrigo Santos (Age 51)
    Member of Management Board & President of the Crop Science Division
    Comp: $2.17M
  • Ms. Heike Prinz (Age 60)
    Chief Talent Officer, Labor Director & Member of Management Board
    Comp: $1.33M
  • Mr. Julio Triana (Age 58)
    Member of Management Board & President of Consumer Health Division
  • Dr. Sebastian Guth Ph.D.
    Chief Operating Officer
  • Dr. Jost Reinhard (Age 52)
    Head of Investor Relations
  • Mr. Michael Preuss
    Head of Communications, Government Relations and Corporate Brand

Should I Buy Bayer Aktiengesellschaft Stock? BAYN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Bayer Aktiengesellschaft:

  • Bayer Aktiengesellschaft has shown resilience in its stock price, currently trading at an attractive valuation, making it a potential value investment opportunity.
  • The company has a diverse product portfolio, including pharmaceuticals, consumer health, and crop science divisions, providing stability and potential for growth across different sectors.
  • Bayer's recent focus on innovation and research & development has led to the introduction of cutting-edge products like the latest versions of its pharmaceuticals and crop protection solutions, enhancing its competitive edge in the market.
  • The company's strong global presence and established brand reputation contribute to its ability to capture market share and expand into new markets, offering long-term growth prospects for investors.
  • Bayer's commitment to sustainability and environmental responsibility aligns with the growing ESG (Environmental, Social, and Governance) investing trend, attracting socially conscious investors.

Cons

Investors should be bearish about investing in Bayer Aktiengesellschaft for these reasons:

  • Bayer faces ongoing legal challenges and settlements related to its acquisition of Monsanto, which could lead to financial uncertainties and reputational risks for the company.
  • The competitive landscape in the pharmaceutical and agricultural sectors is intense, with potential pricing pressures and regulatory hurdles that may impact Bayer's profitability and market position.
  • Fluctuations in commodity prices and currency exchange rates can affect Bayer's earnings, especially in its crop science division, exposing investors to volatility in financial performance.
  • Concerns about potential side effects or regulatory issues related to Bayer's pharmaceutical products could lead to market backlash and impact the company's revenue streams and stock performance.
  • Global economic conditions and geopolitical factors may influence Bayer's operations and sales, posing risks to investors in terms of market uncertainties and macroeconomic challenges.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, June 6, 2024. Please send any questions or comments about these Bayer Aktiengesellschaft pros and cons to contact@marketbeat.com.

BAYN Stock Analysis - Frequently Asked Questions

How have BAYN shares performed in 2024?

Bayer Aktiengesellschaft's stock was trading at €33.63 at the start of the year. Since then, BAYN stock has decreased by 16.5% and is now trading at €28.09.
View the best growth stocks for 2024 here
.

Is Bayer Aktiengesellschaft a good dividend stock?

Bayer Aktiengesellschaft (ETR:BAYN) pays an annual dividend of €0.11 per share and currently has a dividend yield of 0.40%.

What other stocks do shareholders of Bayer Aktiengesellschaft own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bayer Aktiengesellschaft investors own include NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Lam Research (LRCX), QUALCOMM (QCOM), SAP (SAP), AbbVie (ABBV), Applied Materials (AMAT) and Advanced Micro Devices (AMD).

This page (ETR:BAYN) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners